Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. joint Schedule 13G discloses that Full Succeed International Limited is the record holder of 651,465 shares of common stock, representing 6.3% of the class based on 10,347,232 shares outstanding as of February 19, 2026. The statement is jointly filed by Full Succeed, and its directors Nengyuan Pan and Wei Lu, who share voting and dispositive power over the shares held by Full Succeed. Each individual disclaims beneficial ownership except for any pecuniary interest. The joint filing is signed and includes a Joint Filing Agreement.
20/20 Biolabs, Inc. chief executive officer Jonathan Cohen filed a Schedule 13D reporting a significant ownership stake in the company’s common stock. He beneficially owns 1,833,750 shares, including 467,350 shares he can acquire within sixty days through vested stock options.
This position represents 16.8% of the outstanding common stock, based on 10,442,438 shares outstanding as of March 3, 2026. Cohen’s holdings come from shares issued for services at the company’s formation and several stock option grants in 2000, 2023, 2024, and 2026. He states he has no current plans for corporate changes related to this stake.
20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock. The options were granted at an exercise price of $0.0000 per share and are held directly.
According to the terms, these options vest in equal quarterly installments over four years, contingent on Cohen’s continued service with the company. After this grant, he holds stock options for 352,936 shares in total, aligning his compensation more closely with the company’s long-term performance.
20/20 Biolabs, Inc. ownership filing: Streeterville Capital LLC reports beneficial ownership of 543,680 shares, representing 9.99% of the company's common stock. The filing cites 5,442,249 shares outstanding as of February 18, 2026 and attributes the position to warrants and Series E convertible preferred rights subject to a contractual 9.99% ownership cap.
The report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, who is identified as manager/sole member; voting and dispositive power is reported as sole for 543,680 shares.